SCHEMBL533063

SCHEMBL533063

CC(=O)c1cccc(S(=O)(=O)Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.55
LMNA P02545 3/20 0.55
KMT2A Q03164 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
POLB P06746 1/20 0.46
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ACLY P53396 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5563981 0.93 ALDH1A1 (0.50) ALDH1A1LMNAKMT2ASMN1; SMN2HSD17B10
SCHEMBL6888383 0.84 LMNA (0.54) ALDH1A1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL35218 0.82 ALDH1A1 (0.46) ALDH1A1LMNAKMT2ASMN1; SMN2HTT
SCHEMBL212547 0.82 ALDH1A1 (0.57) ALDH1A1LMNAKMT2ASMN1; SMN2HTT
SCHEMBL29792725 0.82 F2 (0.57) ALDH1A1KMT2AHSD17B10TDP1CA12
SCHEMBL30525020 0.82 ALDH1A1 (0.46) ALDH1A1LMNAKMT2ASMN1; SMN2HTT
SCHEMBL4638087 0.82 ALDH1A1 (0.57) ALDH1A1LMNAKMT2ASMN1; SMN2HTT
SCHEMBL35030 0.82 F2 (0.57) ALDH1A1KMT2AHSD17B10TDP1CA12
SCHEMBL11585746 0.81 ALDH1A1 (0.55) ALDH1A1LMNAKMT2ASMN1; SMN2HTT
Ammonia Solution, Strong SCHEMBL15575570 0.81 ALDH1A1 (0.45) ALDH1A1LMNAKMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 US disclosed
US-20260070917-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-12 US disclosed
EP-4665332-A2 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF Differentiated Therapeutics Inc (US) 2025-12-24 EP disclosed
US-20250281620-A1 HYDROXYBISPHOSPHONIC DERIVATIVES OF MELOXICAM FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES ATLANTHERA (FR) 2025-09-11 US disclosed
CN-115066428-B Boric acid derivatives 首药控股(北京)股份有限公司 2025-06-13 CN disclosed
EP-3728194-B1 QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS OTAGO INNOVATION LTD (NZ) 2025-06-04 EP disclosed
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF PRISM MEDICINES, INC. 2025-01-09 US disclosed
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF MBD Co., Ltd. (KR) 2024-08-29 US disclosed
WO-2024173412-A2 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS, INC. (US) 2024-08-22 WO disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 US disclosed
EP-1222163-A1 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS Aventis Pharma Deutschland GmbH (DE) 2002-07-17 EP disclosed
WO-2001025189-A1 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-04-12 WO disclosed
EP-0063808-B1 PHOTOGRAPHIC ELEMENTS CONTAINING NONDIFFUSIBLE 6-(2-THIENYLAZO)-3-PYRIDINOL CYAN DYE-RELEASING COMPOUNDS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-09-18 EP disclosed
EP-0063808-A1 Photographic elements containing nondiffusible 6-(2-thienylazo)-3-pyridinol cyan dye-releasing compounds EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1982-11-03 EP disclosed
US-4163810-A Ultraviolet curable powder paints SCM CORPORATION (US) 1979-08-07 US disclosed
US-4129488-A Ultraviolet curable epoxy-polyester powder paints SCM CORPORATION (US) 1978-12-12 US disclosed
US-4105518-A POLYMER CONTAINING ACRYLYL, ACRYLAMIDE OR ALLYL UNSATURATED GROUPS, REACTED WITH SECONDARY AMINE AND NEUTRALIZED, SENSITIZER SCM CORPORATION (US) 1978-08-08 US disclosed
US-4052280-A PHOTOSENTIZER IN BACKBONE OF POLYMER SCM CORPORATION (US) 1977-10-04 US disclosed
US-4040925-A PAINTS; CHEMICALLY BONDED ULTRAVIOLET SENSITIZER SCM CORPORATION (US) 1977-08-09 US disclosed
US-4039414-A ACRYLYL, ACRYLAMIDE, OR ALLYL POLYMERS, BENZALDEHYDE SENSITIZER SCM CORPORATION (US) 1977-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF CYP4B1, CYP4A11, CYP3A4 ALDH1A1 268/4885LMNA 3776/4885KMT2A 1455/4885
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 ALDH1A1 289/4885LMNA 3518/4885KMT2A 1031/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 ALDH1A1 217/4885LMNA 1803/4885KMT2A 2591/4885
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 ALDH1A1 289/4885LMNA 3518/4885KMT2A 1031/4885
US-20250281620-A1 HYDROXYBISPHOSPHONIC DERIVATIVES OF MELOXICAM FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES BPGM, SOST, HMGB1 ALDH1A1 1094/4885LMNA 3584/4885KMT2A 1971/4885
US-20260070917-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF CDK2, CCNK, CCNC ALDH1A1 2041/4885LMNA 1735/4885KMT2A 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.